PCM
CPRX

Pavaki Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Pavaki Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251K Hold
8,000
– – 0.09% 119
2026
Q1 		$198K Hold
8,000
– – 0.08% 123
2025
Q4 		$187K Buy
+8,000
New +$178K 0.07% 108

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Pavaki Capital Management's CPRX Position: Q2 2026 in Review

Pavaki Capital Management held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 8,000 shares worth $251K. The position accounts for 0.09% of the portfolio, ranked #119.

Pavaki Capital Management first reported a position in CPRX in Q4 2025 and has held it in 3 quarters since. 370 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Pavaki Capital Management held 8,000 shares of Catalyst Pharmaceutical worth $251K as of Q2 2026.
  • Pavaki Capital Management left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
  • Catalyst Pharmaceutical made up 0.09% of Pavaki Capital Management's portfolio in Q2 2026, its #119 holding.
  • Pavaki Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 370 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.